Show simple item record

dc.contributor.authorFrazier, Jean A.
dc.contributor.authorGordon, Charles T.
dc.contributor.authorMcKenna, Kathleen
dc.contributor.authorLenane, Marge C.
dc.contributor.authorJih, Debbie
dc.contributor.authorRapoport, Judith L.
dc.date2022-08-11T08:10:27.000
dc.date.accessioned2022-08-23T17:09:29Z
dc.date.available2022-08-23T17:09:29Z
dc.date.issued1994-06-01
dc.date.submitted2011-02-10
dc.identifier.citationJ Am Acad Child Adolesc Psychiatry. 1994 Jun;33(5):658-63. <a href="http://dx.doi.org/10.1097/00004583-199406000-00006">Link to article on publisher's site</a>
dc.identifier.issn0890-8567 (Linking)
dc.identifier.doi10.1097/00004583-199406000-00006
dc.identifier.pmid8056728
dc.identifier.urihttp://hdl.handle.net/20.500.14038/45835
dc.description.abstractOBJECTIVE: To review the response of 11 adolescents with childhood-onset schizophrenia to a 6-week open clozapine trial. METHOD: Eleven children meeting DSM-III-R criteria for schizophrenia had a 6-week open trial of clozapine (mean sixth week daily dose 370 mg). Behavioral ratings included the Brief Psychiatric Rating Scale and Children's Global Assessment Scale. RESULTS: More than half showed marked improvement in Brief Psychiatric Rating Scale ratings by 6 weeks of clozapine therapy compared to admission drug rating and compared to a systematic 6-week trial of haloperidol. CONCLUSIONS: This open trial indicates that clozapine may be a promising treatment for children and adolescents with schizophrenia who do not respond well to typical neuroleptics. A double-blind placebo-controlled study is ongoing.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=8056728&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1097/00004583-199406000-00006
dc.subjectAdolescent
dc.subjectChild
dc.subjectClozapine
dc.subjectDouble-Blind Method
dc.subjectFemale
dc.subjectHaloperidol
dc.subjectHumans
dc.subjectMale
dc.subjectPsychiatric Status Rating Scales
dc.subjectSchizophrenia, Childhood
dc.subjectPsychiatry
dc.titleAn open trial of clozapine in 11 adolescents with childhood-onset schizophrenia
dc.typeJournal Article
dc.source.journaltitleJournal of the American Academy of Child and Adolescent Psychiatry
dc.source.volume33
dc.source.issue5
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/psych_pp/364
dc.identifier.contextkey1775278
html.description.abstract<p>OBJECTIVE: To review the response of 11 adolescents with childhood-onset schizophrenia to a 6-week open clozapine trial.</p> <p>METHOD: Eleven children meeting DSM-III-R criteria for schizophrenia had a 6-week open trial of clozapine (mean sixth week daily dose 370 mg). Behavioral ratings included the Brief Psychiatric Rating Scale and Children's Global Assessment Scale.</p> <p>RESULTS: More than half showed marked improvement in Brief Psychiatric Rating Scale ratings by 6 weeks of clozapine therapy compared to admission drug rating and compared to a systematic 6-week trial of haloperidol.</p> <p>CONCLUSIONS: This open trial indicates that clozapine may be a promising treatment for children and adolescents with schizophrenia who do not respond well to typical neuroleptics. A double-blind placebo-controlled study is ongoing.</p>
dc.identifier.submissionpathpsych_pp/364
dc.contributor.departmentDepartment of Psychiatry
dc.source.pages658-63


This item appears in the following Collection(s)

Show simple item record